-

Tandem Diabetes Care Announces Upcoming Virtual Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 25, 2022 at 11:00am Eastern Time (8:00am Pacific Time).

The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900
IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900
IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board’s Audit Committee and Cybersecurity and Data Oversight Committee. “We welcome Sandra to our Board of Directors at this pivotal stage in Tandem’s evolution,” said John Sheridan, presid...

Tandem Mobi Receives FDA Clearance for Use with Android Smartphones

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version of the Tandem Mobi mobile app. Tandem Mobi, the world’s smallest, durable automated insulin delivery system 1, is powered by Control-IQ+ technology. Proven Control-IQ+ benefits include: Day 1 improvements2* 79% time in range3† 90% overnight time in range4* “We’re excited...

Tandem Diabetes Care Announces Third Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally Demonstrated year-over-year and sequential gross margin improvement Progressed multi-channel initiative by: Increasing ph...
Back to Newsroom